Background: Abnormal childhood growth may affect future health. Maternal tenofovir (TFV) use was associated with lower body length and head circumference at 1 year of age in HIV-exposed uninfected (HEU) US children. Methods: We studied 509 HEU children in the US-based Surveillance Monitoring of Antiretroviral Therapy Toxicities cohort whose HIV-infected mothers were not using antiretrovirals at the last menstrual period and began combination antiretroviral therapy (cART) in pregnancy (cART initiators). We examined adjusted associations between antiretrovirals and Centers for Disease Control 2000 growth Z scores at 2 years of age within trimester of cART initiation: weight (weight Z score), length (length Z score), weightfor-length [weight-for-length Z score (WFLZ)], triceps skinfold Z score (TSFZ) and head circumference (head circumference Z score). Results: Mothers mean age was 28.6 years; 57% were black non-Hispanic and 19% delivered at <37 weeks gestation. At 2 years, mean weight Z score, length Z score, WFLZ and head circumference Z score were above average (P < 0.05), whereas TSFZ (P = 0.57) did not differ from average. WFLZ was >1.64 standard deviation (SD) (>95th percentile) in 13%. Among children of first-trimester cART initiators, TFV+emtricitabine-exposed children had slightly higher mean WFLZ (0.45 SD; 95% confidence interval: −0.10 to 1.00) and lower TSFZ (−0.55 SD; 95% confidence interval: −1.07 to −0.02) compared with zidovudine+lamivudine-exposed children. TSFZ was lower in those exposed to boosted protease inhibitors. In contrast, growth in children of second trimester cART initiators did not differ by antiretroviral exposures. Conclusion: Growth was above average in HEU; 13% were obese. Maternal TFV use was not associated with lower length or head circumference at 2 years of age, as hypothesized, but may be related to greater weight among those exposed to cART early in pregnancy.
M
ost HIV-infected (HIV+) women in the US are on antiretroviral (ARV) medications at conception or begin early in pregnancy to prevent mother-to-child HIV transmission. 1 Prenatal exposures to infections, including HIV, may alter fetal and postnatal growth, 2 through decreases in placental size or morphologic changes 3, 4 or mitochondrial abnormalities. 5 Little is known about antenatal ARV exposure and growth. Factors that affect fetal programming may affect subsequent growth. 6 Since both fetal growth restriction and subsequent infant obesity are linked to diabetes and cardiovascular disease in adulthood, 7 characterizing growth in general and the effects of specific antenatal ARV exposure on postnatal growth in HIV-exposed uninfected (HEU) children is necessary to optimize therapy and maximize safety. Exposures that occur during the first trimester (organogenesis) compared with later in gestation when there is rapid growth may differentially affect outcomes. In Europe, HEU children to age 10, on average, had normal growth in the periods before and during widespread use of ARVs in pregnancy. 8 In Botswana, HEU children exposed antenatally to combination ARV therapy (cART) after the first trimester had significantly lower length but only small differences in weight (lower) and weight-for-length (higher) Z scores at 6 months than those exposed to short course zidovudine (ZDV). 9 Effects of specific antenatal ARVs on growth in HEU children have not been adequately evaluated in the era of cART, 10 and some results are discrepant. Tenofovir (TFV)-exposed HEU children had lower weight, 11 length and head circumference (HC) 12 in 2 studies, but no difference in growth in other cohorts. 13, 14 We examined average growth and effects of antenatal ARV exposures on growth outcomes in HEU children at 2 years of age. We studied HEU children in the US-based Surveillance Monitoring of ART Toxicities (SMARTT) cohort of the Pediatric HIV/AIDS Cohort Study within trimester of cART initiation, comparing common therapies such as TFV-versus ZDV-containing regimens and any protease inhibitor (PI) regimen boosted with ritonavir [boosted protease inhibitor (bPI)] versus any PI regimen not boosted with ritonavir.
MATERIALS AND METHODS

Population and Data Collection
SMARTT prospectively enrolled 2 cohorts of HEU children at 22 clinical sites across the US and Puerto Rico to evaluate the safety of ARVs used in pregnancy on childhood outcomes. Between 2007 and 2009, the static cohort enrolled HEU children <12 years of age and their mother or caregiver. Since 2007, the dynamic cohort has enrolled HIV+ mothers and their infants from 22-week gestation until 1-week postpartum with continued enrollment to monitor safety of newly prescribed ARVs in pregnancy. At entry, the mother or caregiver was interviewed to obtain sociodemographic characteristics and history of substance use during this pregnancy. Pregnancy data abstracted from medical charts included obstetric complications, ARV use, CD4 T cell (CD4) count and percent (CD4%) and HIV viral load. At annual visits, children's growth measurements and health histories were obtained. The SMARTT protocol was approved by the institutional review boards at Harvard and each site. Informed consent was obtained from all mothers or caregivers for their own and their children's participation.
Inclusion Criteria
Estimates of the exposure-outcome relationship may be biased when prevalent and incident exposures are included together, as it is difficult to control for confounding by indication. 15, 16 Thus, we studied incident cART users and excluded those who were exposed to ARV at conception. We included HEU children whose mothers were not on any ARV at their last menstrual period (LMP) and for whom the first ARV regimen during this pregnancy was cART (cART initiators). cART was defined as at least 3 ARVs from at least 2 different classes. Any mothers who had received ARVs before the current pregnancy (during a prior pregnancy or for their own health) were only included in this analysis if they had stopped ARVs before their LMP. Others may never have used ARVs. We further limited this analysis to HEU children whose mothers had complete ARV information by trimester and who had weight and length measurements at 2 years ± 4 months of age as of April 1, 2013.
Growth Outcomes
Birth weight and diagnosis of intrauterine growth restriction were abstracted from the obstetrical chart. Anthropometric measurements were performed in triplicate at entry and annually thereafter by trained personnel. 17 In the dynamic cohort, neonatal measures were generally obtained within 72 hours of birth (72%), but accepted within 14 days of birth. When weights (kg) were measured, infants could wear undergarments, but not diapers. Length (cm) was measured in the recumbent position on a board with legs fully extended until age 3. If the child's length exceeded that of the board, standing height was measured without shoes using a wall-mounted stadiometer, based on Centers for Disease Control recommendations when our protocol was written. Triceps skinfold thickness (TSF, mm) and HC (cm) were measured by standard techniques 18 . Body mass index Z score was calculated, rather than WFLZ, when standing height was measured. For preterm children (<37 weeks gestation), Z scores for birth weight and neonatal weight and length (within 2 weeks of birth) were calculated for gestational age. 20 WTZ, LNZ and WFLZ values <−5 and >5 standard deviations (SDs) were excluded because they were highly influential in the analysis. At age 2, we compared the mean of each growth Z score to a mean of zero using a Student's t test. WTZ, LNZ, WFLZ/body mass index Z score and TSFZ were each categorized into low, normal and high: <−1.64, −1.64 to 1.64 and >1.64, respectively. These correspond to <5th, 5th-95th and >95th percentiles, respectively. HCZ was categorized as <−2 SD, −2 to 2 SD and >2 SD, per the protocol. Children with WFLZ >1.64 were considered obese. Small for gestational age (SGA) was defined as birth weight <10th percentile corrected for gestational age.
Statistical Methods
We fit unadjusted and adjusted general linear regression models to evaluate the association of each ARV exposure at maternal cART initiation on each growth outcome at age 2 years, separately for first trimester (LMP through 14 weeks gestation) and second trimester (15 through 28 weeks gestation) of cART initiation. We compared common regimens including TFV+emtricitabine (FTC) versus ZDV+lamivudine (3TC) and bPI versus unboosted PI based on results of previous studies of fetal growth or early infant growth. 11, 12, 21 This is a comparative safety strategy. 15, 16, 22 We also compared exposed versus unexposed to each PI and nucleoside reverse transcriptase inhibitors (NRTIs) used by at least 10% of women during pregnancy. Changes in regimen were not considered as this analysis was the observational study equivalent of an intention-to-treat analysis. 22 SMARTT is a drug safety study so our priority was to limit type II statistical errors (falsely missing a safety signal) rather than type I errors (falsely rejecting the null hypothesis). Thus, we made no adjustments for multiple testing and pointed out results with P < 0.10. 23, 24 Adjusted models included site geographic region and maternal covariates that were associated with the outcome with P < 0.20 in univariable analyses and deemed to be confounders if they changed the estimate of exposure >10% or improved estimate precision for that outcome in the adjusted analysis. We performed sensitivity analyses limited to children whose mothers had CD4% and viral load before cART initiation in pregnancy. In addition, we evaluated the effect of TFV on growth among children whose mothers were on a PI-based regimen.
Based on a priori knowledge, directed acyclic graphs were drawn using DAGitty v2.0 (Utrecht, The Netherlands) 25 to identify potential confounders of the relationship between the main exposure (ARV type) and growth outcomes at 2 years of age. Potential confounders measured at or before cART initiation included mothers' age, being born in mainland US, race/ethnicity, speaking only English at home, household income, first-trimester use of illicit drugs, alcohol or tobacco during the pregnancy, CD4% and HIV RNA > 10,000 copies/mL before cART initiation in pregnancy, prepregnancy BMI, everused ARV before this pregnancy, birth year of child and geographic region of the clinic. We used CD4% rather than CD4 count because this is more stable in pregnancy. We also tested random effect models to account for clustering of children within site or between siblings and performed sensitivity analyses omitting siblings and twins.
RESULTS
Maternal and HIV-exposed Infant Characteristics
We included 509 children (Fig. 1) ; 72% (365/509) of whom were from the dynamic and 28% (144/509) from the static cohort. HIV+ mothers had a mean age of 28.6 years, and 57% were black non-Hispanic (Table 1) . First-trimester use of illicit drugs, alcohol and tobacco was reported by 7%, 8% and 19%, respectively. Of the 83% with CD4% and viral load information available before cART initiation in pregnancy, 45% had CD4% <25 and 41% had viral load >10,000 copies/mL (Table 2) . Ninety-seven (19%) deliveries were preterm; 9 of these infants were SGA. Of the 28 sibling pairs, 7 pairs were twins, and 1 twin in each of 2 pairs was SGA. Mean WTZ and LNZ at birth, adjusted for gestational age, were −0.44 and −0.34, respectively. ARV use before this pregnancy was reported by 148 (29%), not used by 132 (26%), and unknown in 229 (45%) women. Of the 509 women, 27.1% initiated cART in the first trimester, 64% in the second trimester and 8.5% in the third trimester. First-trimester cART initiators were significantly older. Trimester of initiation varied by geographic site.
ARV Exposure by Trimester of cART Initiation
At cART initiation, maternal NRTI use included 3TC+ZDV (67%), TFV+FTC (24%), 3TC+ZDV+abacavir (5%) and 3TC+abacavir (2%) ( Table 2) . Any TFV was used by 25%. Boosted PI-based cART was received by 74%, nonboosted PI 22% and no PI by 4%; 5% received non-NRTI. Other ARV agents were used by <10% of women. First-trimester cART initiators used a boosted PI less frequently and were more likely to receive nelfinavir. Tables  (Supplemental Digital Content 
HEU Growth Outcomes at 2 Years of Age
At 2 years of age, mean WTZ, LNZ, WFLZ and HCZ were all greater than zero (all P < 0.05), whereas TSFZ did not differ from zero (P = 0.57) ( Table 3 ). The percentage with high Z scores (see methods) was 13% for WFLZ, 11% for WTZ, 10% for TSFZ, 7% for HCZ and 6% for LNZ. In contrast, the percentage with low Z scores was small for each of these outcomes: 5% WFLZ, 7% for WTZ, 6% for TSFZ, 1% for HCZ and 5% for LNZ. Standing height rather than length was measured in 2 of 138 children 21-24 months of age and 16 of 371 24-27 months of age. Table 4 shows unadjusted and adjusted models of the association of each ARV with each growth outcome by trimester of cART initiation.
Unadjusted and Adjusted Models of ARVs on Growth Outcomes in HEU at Age 2 Years
First-trimester cART Initiators
Among children of first-trimester cART initiators (Table 4 and Fig., Supplemental Digital Content 5, http://links.lww.com/ INF/C578), WTZ at 2 years of age was, on average, 0.44 SD higher in HEU children exposed to TFV+FTC compared with ZDV+3TC at maternal cART initiation after adjustment (Table 4) . When TFV exposure was compared with no TFV exposure, ignoring other NRTIs used, WTZ was 0.50 higher. No other ARVs were associated with WTZ. For all ARVs studied, differences in mean LNZ between those exposed versus unexposed were small and 95% confidence intervals (CIs) were wide (Table 4 and 12 (9) 20 (6) 3 (8) 35 (7) 0.67 Alcohol-used in first trimester, n (%)
15 (11) 21 (7) 3 (8) 39 (8) 0.30 Tobacco-used in first trimester, n (%)
31 (23) 54 (17) 7 (18) 
10 (7) 13 ( 10 (10) 27 (13) . The questions regarding ARV use before pregnancy and date of prenatal visit were first collected in 2010 and thus were unavailable for 218 participants. Of those administered the questionnaire, ARV use before pregnancy was unknown for N = 11 and prenatal date was unknown for 220 (13 additional had uninterpretable prenatal care dates). P values for pregnancy complications were not computed because there were different frequencies of missing by trimester.
†Birth weight, maternal weight and height and pregnancy complications were abstracted from the clinical charts. ‡Length was measured in SMARTT within 14 days after birth. For children born <37 weeks gestation, both weight and length were adjusted for gestational age using Fenton et al 20 norms. For children born ≥37 weeks, CDC norms were used. Length within 2 weeks of delivery was missing on N = 166. This was primarily because children in the static cohort did not have measures of length at or near delivery (N = 155), so weight-for-length could also not be calculated.
BMI indicates body mass index; CDC, Centers for Disease Control; NY-NJ, New York/New Jersey; WT, weight; cART, combination antiretroviral therapy.
WTZ and WFLZ were each higher in the TFV+FTC-exposed versus ZDV+3TC-exposed and remained when adjusted for bPI. TSFZ was 0.55 lower in those whose mother received TFV+FTC compared with ZDV+3TC and 0.61 lower in bPI versus non-bPI. The association of TFV+FTC on TSFZ remained after adjustment for bPI (−0.60, 95% CI: −1.10 to −0.095), while that for bPI was attenuated (−0.49, 95% CI: −1.10 to 0.10) when both were in the model. No associations were found for HCZ. In sensitivity analyses restricted to children of mothers with CD4% and viral load measures available before cART initiation, results were similar to those reported in the complete dataset above (not shown). In addition, adjustment for CD4% and viral load did not affect estimated ARV associations, suggesting no confounding by disease severity. The results did not change when a random effect was included for site or siblings or when twins were excluded.
Second-trimester cART Initiators
In contrast to children of first-trimester cART initiators, there were no differences at P < 0.10 in WTZ, LNZ, WFLZ, TSFZ or HCZ, by exposure to TFV or other ARVs among children of second-trimester cART initiators. (Table 4 and Fig., Supplemental Digital Content 5, http://links.lww.com/INF/C578). However, LNZ was 0.23 (95% CI: −0.06 to 0.53; P = 0.12) higher in those exposed to bPI versus nonboosted PI. All of these results were consistent in the subset with available measures of maternal CD4 and viral load data before cART initiation (not shown). Again, the results did not change when a random effect was included for site or siblings or when twins were excluded.
DISCUSSION
With the success of prevention of mother-to-child HIV transmission, the HEU population is increasing worldwide. It is essential to monitor this population for possible adverse outcomes related to antenatal ARV exposure. This group of HEU children in the US whose mothers initiated cART during pregnancy had lower than average birth weight and length, but 13% were obese at 2 years of age. The prevalence of low growth was not greater than expected. Among children of first-trimester cART initiators, WTZ and WFLZ were greater and TSFZ lower for those exposed to TFV+FTC versus ZDV+3TC and persisted when comparing TFVexposed to TFV-unexposed children. Boosted PI was associated with lower TSFZ. However, we observed no effects of ARV exposure on growth among second-trimester cART initiators.
Exposures during critical fetal development periods can induce persistent changes in body structure or function, and have long-term effects on health. 26 Thirteen percent of our cohort was obese at 2 years of age when compared with a national sample of similar age where the prevalence was 8.1% (95% CI: 5.8-11.7) for all races and 8.4% (95% CI: 4.6-14.9) in non-Hispanic blacks. 27 In addition, in unpublished data from our cohort, among 3-year old children, HEU had a significantly higher rate of obesity compared with HIV-unexposed children (13.6% vs. 3.2%) from the same clinical sites, even after adjustment for race/ethnicity. However, these HIV-unexposed children may differ from the HEU on other factors, including other socioeconomic status, birth weight and length on which we do not have data, which can influence later growth. Low birth weight and more rapid catch-up growth in early childhood can increase the risk of obesity, insulin resistance and metabolic syndrome in childhood, 28 and early coronary heart disease in adulthood. 7 Childhood obesity is now epidemic in most racial, ethnic and economic categories in the US, but it is especially high in black, Hispanic and poor communities, which comprise the majority of our HEU. Formula feeding, poor diet and lack of physical activity also impact obesity. These factors, combined with potential additional effects of in utero ARV exposures, may elevate HEU children's risk of cardiovascular disease in adulthood.
We expected that length and HC at age 2 years would be lower in HEU children exposed to TFV in utero, based on previous results at age 1 in SMARTT. 12 However, we found no significant differences in these outcomes at 2 years, regardless of trimester of cART initiation. It is possible that TFV-exposed children caught up in length by age 2, as shown by Gibb et al 13 Alternatively, our results (28) 68 (21) 13 (30) 120 (24) 3TC+ZDV+ABC 7 (5) 16 (5) 1 (2) 24 (5) 3TC+ABC 6 (4)
PI with RTV 97 (75) 239 (76) 38 (93) 374 (77) 0.04 PI without RTV 33 (25) 74 (24) 3 (7) 110 (23) Atazanavir 28 (20) 42 (13) 7 (16) 77 (15) 0.12 Nelfinavir 29 (21) 69 (21) 2 (5) 100 (20) may differ due to study design as we limited analyses to women who initiated cART during the current pregnancy to decrease bias from combining prevalent and incident users. 16 We also had limited power to detect small differences by TFV or other ARVs.
Among children of first-trimester cART initiators, we found greater WTZ and WFLZ at age 2 years in those exposed to TFV+FTC versus ZDV+3TC. Mean WTZ and WFLZ were greater than zero in both groups, but we cannot determine if TFV+FTC had a biologic effect on growth or if ZDV+3TC might have mitigated expected weight gain. 29 However, we observed no association of TFV+FTC with WTZ or WFLZ among children of second-trimester cART initiators. The first trimester may be a vulnerable time for programming of later growth in HEU children, despite similarities in fetal growth. Fetal transfer of drug can be influenced by specific drug transporters 30 and the levels of drug transporters change during gestation. In addition, TFV and ZDV are transported on different receptors. It is possible that these factors may explain why we only saw differences in growth between TFV and ZDV only among those exposed during the first trimester. The placenta regulates nutrient transfer to the fetus. However, some nutrient transporters, such as equilibrative nucleoside transporter 1/SLC29A1, also transport ARVs such as ZDV. Thus, ZDV may competitively inhibit nutrient transfer to the fetus, potentially affecting growth outcomes. 31, 32 Among children of first-trimester cART initiators, TSFZ was lower in TFV+FTC versus ZDV+3TC and in bPI versus nonboosted PI-exposed. Limb fat atrophy because of PIs has been described in children and adults. 33 In contrast, switching from ZDV to TFV improved limb fat in adults. 34 It is not known if or how ARVs may affect fat accumulation of HEU in utero or during early childhood. The timing of these NRTI exposures may explain their differential effects by trimester. 35, 36 We do not know why women were prescribed their current or previous ARVs. Among women with available data, pre-cART CD4 and viral load did not differ by trimester of initiation, but first-trimester initiators were more likely to have been on ARV before this pregnancy. We do not know why mothers had a lapse in treatment and restarted after the pregnancy began. While we did not observe confounding by clinical markers or prior ARV use, unmeasured confounding could explain differences across trimester. Also, infants of women treated with ARV in the first trimester had longer exposure to ARV and were less likely to experience exposure to prolonged maternal viremia, but there was no difference in the percent with suppressed viral load in the third trimester. However, women may have experienced greater cytokine production in the first trimester as a result of ART initiation. 37 However, it is not known whether increased inflammation during this critical time period could impact growth. . Alcohol and tobacco use are during the first trimester. Adjusted models include the following covariates for each outcome by trimester of cART initiation: WTZ 1st (site region, alcohol, tobacco and language at home); WTZ 2nd (site region and language at home); LNZ 1st (site region, alcohol and tobacco); LNZ 2nd (site region, tobacco, language at home and living arrangement); WFLZ 1st (site region, alcohol and language at home); WFLZ 2nd (site region, tobacco and language at home); TSFZ 1st (site region, alcohol, tobacco and birth year); TSFZ 2nd (site region and living arrangement); HCZ 1st (site region, alcohol and tobacco); HCZ 2nd (site region, tobacco, income and language at home). Marital status, race/ethnicity, birth outside the mainland US and prior ARV use did not cause confounding and were not included. *Separate unadjusted and adjusted linear regression models fit for each ARV and each Z score outcome at trimester of cART initiation in pregnancy. Average difference is in those exposed compared with those unexposed for each ARV. ATV indicates atazanavir; CDC, Centers for Disease Control; NFV, nelfinavir.
We evaluated the total effect of ARVs on growth outcomes, not distinguishing indirect and direct effects (eg, through low birth weight and/or prematurity). Factors associated with prematurity were previously reported. 38 There could also be survival bias because of early fetal loss related to specific ARVs. We did not collect dietary data and could not determine if certain dietary habits explained the higher than expected rate of obesity in HEU children. Similarly, we did not have a comparison group of HIV-unexposed 2 years old of similar sociodemographic status to compare rates of obesity. We only had a group of HIV-unexposed 3 years old as mentioned above. Additionally, our results may only apply to the US population of HEU.
The rate of childhood obesity has climbed dramatically in the US over the last 30 years with a concomitant and worrisome rise in risk factors for cardiovascular disease and diabetes. The differential associations of ARV exposures with growth that we found underscore the importance of determining if and how specific antenatal ARV exposures contribute to the risk of obesity and its longterm consequences so that specific ARVs perhaps can be avoided during critical periods in pregnancy.
